Fish Oil in Surgical Recovery: Can It Improve Outcomes?
"Discover how intravenous fish oil emulsions are changing post-operative care for critically ill patients, reducing inflammation and improving recovery times."
For years, the standard intravenous lipid emulsions (ILEs) used in U.S. hospitals were primarily composed of soybean oil. While these provided necessary nutrition, clinicians observed a potential downside: the pro-inflammatory nature of soybean oil's long-chain triglycerides (LCTs). This sparked interest in alternative ILE blends already in use in Europe and China, which incorporated fish oil (FO), olive oil (OO), and medium-chain triglycerides (MCTs).
In 2016, the FDA approved the first alternative composite mixed-oil ILE for use in adult patients. This blend contains soybean oil (30%), MCTs (30%), OO (25%), and fish oil (15%). This approval has opened the door to new strategies for managing nutrition in critically ill surgical patients, especially those requiring parenteral nutrition (PN).
This article examines the evidence surrounding fish oil-containing ILEs (FO ILEs) and their impact on clinical outcomes. By reviewing recent studies, we aim to understand whether FO ILEs can improve recovery, reduce complications, and support overall health in surgical patients.
A Phase II Trial in Cardiac Surgery
ClinicalTrials.gov lists NCT06279793, a randomized, placebo-controlled Phase II multicenter trial of intravenous fish oil-based lipid emulsion in high-risk cardiac surgery patients. The listing is dated February 28, 2024. A 2018 review describes the clinical background for intravenous fish oil in critically ill and surgical patients and evaluates results using a product-specific meta-analysis. The listed sources do not provide trial outcome figures or current population-level statistics.
From Clinical Background to Early Feeding
A review of intravenous fish oil in critically ill and surgical patients sets out to explain its historical and clinical background, assess results through a product-specific meta-analysis, and stimulate further research into fish oil’s immune-modulatory potential. The supplied excerpt also notes a study finding that both omega-3 and omega-6 fatty acids would prolong an unspecified outcome, but does not identify that outcome. Separately, a surgical nutrition article describes a shift from “wait and see” toward “feed early,” alongside growing interest in specialized formulas containing fish oil.
What the Research Says: Fish Oil's Benefits for Surgical Patients
Research suggests that FO ILEs offer several advantages over traditional soybean oil-based emulsions, particularly in managing triglyceride levels, reducing inflammation, and supporting liver function. These benefits can lead to improved morbidity and mortality outcomes in critically ill surgical patients.
- Lower Incremental Increases: A study of gastrointestinal surgery patients found that an FO ILE blend led to significantly lower incremental increases in serum triglycerides compared to a traditional MCT/LCT emulsion.
- Protective Against Rapid Spikes: Another study in surgical ICU patients demonstrated that an MCT:LCT:FO emulsion resulted in significantly lower serum triglyceride levels by day 4 compared to an MCT:LCT emulsion.
- Maintaining Healthy Levels: While some studies showed increases in triglyceride levels in both FO and non-FO groups, levels remained within safe limits (<250 mg/dL), with FO groups often showing better control.
Laboratory Interference and Clinical Signals
A study focused on Roche Cobas 6000 examines whether fish oil-based lipid emulsions used in total parenteral nutrition and lipid rescue therapy interfere with common laboratory analytes; its supplied snippet says studies of lipaemic interference with newer fish oil-based emulsions remain scarce. A post-hoc analysis of the INSUPAR Study addresses triglyceride levels in non-critically ill patients with type 2 diabetes receiving total parenteral nutrition. Its excerpt also reports that several cited studies found shorter hospital stays, especially among ICU surgical patients, and fewer infectious complications with fish oil-based emulsions than with mainly pure soybean-oil or MCT/LCT emulsions. A review of critically ill patients in the context of ESPEN guidelines reports associations involving triglyceride concentrations, inflammatory markers, and liver-function enzymes, but the snippet does not specify further study details.
Olive Oil Versus Fish Oil in Parenteral Nutrition
A review comparing olive- and fish-oil-based parenteral nutrition excluded evidence that was non-experimental, involved animals or children, concerned home parenteral nutrition, or combined parenteral with enteral or oral nutrition; it also excluded a conference abstract unavailable as a full-text publication. A 2025 review describes fish oil as rich in omega-3 PUFAs that may support active resolution of inflammation without impairing host defenses, and may facilitate recovery and help preserve muscle mass. The 2026 comparison concludes that replacing soybean oil with either olive or fish oil may offer similar benefits, while emphasizing the need for more high-quality research to guide practice.
The Future of Surgical Nutrition: Embracing Fish Oil Emulsions
The research is compelling: incorporating fish oil into intravenous lipid emulsions offers significant benefits for surgical patients. From managing triglyceride levels and tamping down inflammation to potentially improving liver function and clinical outcomes, FO ILEs represent a promising advancement in nutritional support.
Promising Findings, Unsettled Questions
The Omega-3 study’s conclusions state that fish oil supplementation did not increase peri-operative bleeding and reduced the number of blood transfusions; higher achieved n-3-PUFA levels were associated with lower bleeding risk. The authors say these findings support reconsidering recommendations to stop fish oil or delay procedures before cardiac surgery. A systematic review and meta-analysis of randomized controlled trials in major abdominal surgery, covering studies published through December 2022, examined omega-3 PUFAs and postoperative inflammation. Its source excerpt calls for further studies before reaching a better-informed verdict.
Surgical Outcomes in a Systematic Review
A systematic review of randomized controlled trials from Europe and Asia, published by Wei, Hua, Bin, and Klassen in Nutrition in 2010, assessed fish-oil-containing lipid emulsions in surgical patients. The supplied conclusion says administration to patients undergoing elective major operations improved outcomes, with significantly fewer infectious complications and a significantly shorter hospital stay. The provided source material does not give effect sizes or details about variation among the included trials.
Patient Outcomes in the Evidence Base
A systematic review by Wei, Hua, Bin, and Klassen aimed to assess the clinical efficacy of fish-oil-containing lipid emulsions in surgical patients. The researchers searched Medline, SCI, Embase, the Cochrane Library, and the Chinese Biomedicine Database for randomized controlled trials published before January 1, 2009, involving postoperative patients. A 2023 review excerpt notes that some studies found reduced inflammation, improved gas exchange, and shorter hospital stays among critically ill patients who received fish oil. These excerpts describe reported study findings rather than individual patient experiences.
While more research is always valuable, the existing evidence makes a strong case for considering FO ILEs as a standard of care for surgical patients requiring parenteral nutrition. As healthcare providers, staying informed about these advancements allows for providing the best possible care and promoting faster, more complete recoveries.
By understanding the potential of FO ILEs and carefully considering individual patient needs, clinicians can leverage these innovative emulsions to optimize nutrition, reduce complications, and improve overall outcomes in the surgical setting.